Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.83 |
| ▸ | NOS3 | P29474 | 6/20 | 0.83 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.83 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.83 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6620545 | 0.91 | NOS1 (1.00) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL6617436 | 0.90 | NOS1 (0.83) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL6620863 | 0.90 | NOS1 (0.83) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL6623521 | 0.87 | NOS1 (0.78) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL6618617 | 0.84 | NOS1 (0.85) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL27613058 | 0.83 | NOS1 (0.61) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL27554919 | 0.81 | NOS1 (0.63) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL6622079 | 0.79 | NOS1 (0.78) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL27554920 | 0.79 | NOS1 (0.66) | NOS1NOS3CHRM2CHRM4DRD2 | |
| SCHEMBL6618161 | 0.79 | NOS1 (1.00) | NOS1NOS3CHRM2CHRM4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1471055-A1 | 6-phenylpyridyl-2-amine derivatives | PFIZER INC. (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-0891332-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | LOWE JOHN A (US) | 2002-10-17 | — | — | US | disclosed |
| US-6465491-B2 | NITRIC OXIDE SYNTHASE INHIBITOR; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | LOWE JOHN A (US) | 2001-10-25 | — | — | US | disclosed |
| US-6235747-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | NOS2, NOS3, NOS1 | NOS1 3/4885NOS3 2/4885CHRM2 151/4885 |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | NOS1, NOS3, NOS2 | NOS1 1/4885NOS3 2/4885CHRM2 284/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | NOS1 1/4885NOS3 2/4885CHRM2 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.